Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation

Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement for hematologic malignancies, with some patients achieving long-term remission. However, the majority of treated patients still die of their disease. A consistent predictor of response is tumor quantity, wherein a higher d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Alexander B., Chou, Ssu-Yu, Kang, Solomon, Kwon, Eric, Inkman, Matthew, Szymanski, Jeff, Andruska, Neal, Colgan, Cian, Zhang, Jin, Yang, Joanna C., Singh, Nathan, DeSelm, Carl J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509663/
https://www.ncbi.nlm.nih.gov/pubmed/37093643
http://dx.doi.org/10.1182/bloodadvances.2022009543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509663/
https://www.ncbi.nlm.nih.gov/pubmed/37093643
http://dx.doi.org/10.1182/bloodadvances.2022009543

Ejemplares similares